ACADIA Pharmaceuticals Zukünftiges Wachstum
Future Kriterienprüfungen 1/6
ACADIA Pharmaceuticals wird ein jährliches Gewinn- und Umsatzwachstum von 12.1% bzw. 10.1% prognostiziert. Der Gewinn pro Aktie wird voraussichtlich wachsen um 9.7% pro Jahr. Die Eigenkapitalrendite wird in 3 Jahren voraussichtlich 17.1% betragen.
Wichtige Informationen
12.1%
Wachstumsrate der Gewinne
9.67%
EPS-Wachstumsrate
| Biotechs Gewinnwachstum | 25.5% |
| Wachstumsrate der Einnahmen | 10.1% |
| Zukünftige Eigenkapitalrendite | 17.12% |
| Analystenabdeckung | Good |
| Zuletzt aktualisiert | 12 May 2026 |
Jüngste Aktualisierungen zum künftigen Wachstum
Recent updates
Narrativ-Update • May 09
ACAD: Remlifanserin Alzheimer’s Psychosis Readout Will Drive Upside From Undervalued Levels
Analysts recently adjusted their fair value estimate for ACADIA Pharmaceuticals slightly lower to $43.55 from $43.97, reflecting updated assumptions for revenue growth, profitability, and future P/E. This revision also incorporates mixed but generally constructive Street price target updates in the $26 to $37 range, along with several fresh Buy and Outperform ratings.
Narrativ-Update • Apr 23
ACAD: Execution Risk Around Rett Syndrome Setback Will Limit Future Upside
Analysts trimmed the fair value estimate for ACADIA Pharmaceuticals slightly to $19.64 from $19.73, as modestly higher discount rate assumptions offset slightly stronger projected revenue growth and profitability. They maintained a supportive stance following a mix of recent price target increases and reductions across the Street.
Narrativ-Update • Apr 08
ACAD: Future Upside Will Depend On Alzheimer Psychosis Trial Outcomes
The fair value estimate for ACADIA Pharmaceuticals has increased slightly to $31.80, as analysts incorporate updated revenue growth assumptions, mixed adjustments to price targets across firms, and ongoing expectations for contributions from Nuplazid, Daybue, and the broader pipeline. Analyst Commentary Recent research coverage on ACADIA Pharmaceuticals shows a mix of optimism and caution, with several firms revising price targets after earnings updates, guidance, and pipeline commentary.Narrativ-Update • Mar 24
ACAD: Remlifanserin Alzheimer’s Psychosis Data Will Drive Upside From Undervalued Levels
ACADIA Pharmaceuticals' updated analyst price target moves from $37 to about $44, with analysts pointing to refreshed models that reflect recent guidance, ongoing commercial momentum in Nuplazid and Daybue, and growing attention on the remlifanserin Phase 2 program in Alzheimer's disease psychosis. Analyst Commentary Recent Street research around ACADIA Pharmaceuticals clusters around refreshed models, updated sales assumptions for Nuplazid and Daybue, and rising interest in the remlifanserin program in Alzheimer's disease psychosis.Narrativ-Update • Mar 10
ACAD: Trofinetide EU Setback And Execution Risks Will Likely Restrain Upside
ACADIA Pharmaceuticals' updated analyst price target reflects a modest reset in fair value to $19.73 from $20.26, as analysts balance recent target revisions across the Street with refreshed assumptions for growth, margins, and future P/E levels. Analyst Commentary Across recent research updates, views on ACADIA are mixed, with several large firms expressing confidence in the commercial trajectory of Nuplazid and Daybue, while others are more measured and focused on execution risks and how much of the current pipeline is already reflected in the share price.Narrativ-Update • Feb 23
ACAD: Pipeline And Execution Risks Will Likely Cap Upside Despite Renewed Optimism
ACADIA Pharmaceuticals' updated fair value estimate has edged up from $19.65 to $20.26 per share, reflecting analysts' higher price targets tied to confidence in Nuplazid and Daybue, as well as underappreciated upside from the remlifanserin pipeline asset. Analyst Commentary Recent research views on ACADIA are mixed, with some firms pointing to upside tied to Nuplazid, Daybue, and the remlifanserin program, while others are more guarded.Narrativ-Update • Feb 09
ACAD: Higher P/E Assumptions Will Rely On Successful Rett Syndrome Expansion
Analysts have nudged their fair value estimate for ACADIA Pharmaceuticals higher by about $0.47 per share, reflecting recent price target revisions and updated assumptions around revenue growth, profitability, and future P/E multiples. Analyst Commentary Recent Street research on ACADIA Pharmaceuticals has been active, with multiple firms revising price targets and updating their views on the company.Narrativ-Update • Jan 25
ACAD: Execution Risk And Sector Capital Pressures Will Likely Constrain Upside
Narrative Update Analysts have lifted their price target on ACADIA Pharmaceuticals to US$40 from US$35, citing updated assumptions around revenue growth, profitability and future P/E expectations, alongside a generally cautious but constructive view on Biotech, with potential M&A activity helping to support the sector. Analyst Commentary While the updated US$40 target signals constructive sentiment on ACADIA Pharmaceuticals, recent commentary still carries a cautious tone around how the story plays out over time.Narrativ-Update • Jan 11
ACAD: Higher P/E Assumptions Will Support Upside If Pipeline Milestones Deliver
Narrative Update Analysts have lifted their price target on ACADIA Pharmaceuticals to US$40 from US$35, citing a refreshed view on fair value, updated discount rate assumptions, and adjusted expectations for revenue growth, profit margin, and future P/E multiples. Analyst Commentary Recent commentary around ACADIA Pharmaceuticals reflects a mix of optimism on potential value creation and caution around sector level capital trends.Narrativ-Update • Dec 26
ACAD: Expanded Neuroscience Pipeline Will Drive Upside From Undervalued Levels
Analysts have modestly increased their price target on ACADIA Pharmaceuticals from 35.00 dollars to 37.00 dollars. They cited slightly stronger long term revenue growth, improved profit margin expectations, a marginally lower discount rate, and a higher projected future price to earnings multiple.Narrativ-Update • Dec 12
ACAD: Upcoming Neuropsychiatric Data Expected To Drive Upside Despite Recent Setback
Analysts have trimmed their price target on ACADIA Pharmaceuticals by $5 to $35 per share. This reflects a modestly higher discount rate and lower long term profit expectations, despite slightly stronger projected revenue growth and reassurance that the ACP-101 failure has only a small impact on overall valuation.Seeking Alpha • Dec 04
Buy Acadia Pharmaceuticals For Daybue/Nuplazid Stability And Pipeline Optionality
Summary Acadia Pharmaceuticals Inc. is rated Buy for its steady NUPLAZID/DAYBUE franchises and pipeline-driven upside potential. NUPLAZID’s patent protection now extends to 2030, supporting >10% Y/Y revenue growth and providing a stable revenue base. DAYBUE missed launch expectations but remains a durable rare-disease asset; ex-U.S. growth is likely to be modest. ACP-204’s mid-2026 Phase 2 data in Alzheimer’s psychosis is a major catalyst; ACAD's financials remain robust and profitable. Read the full article on Seeking AlphaAnalyseartikel • Nov 13
Shareholders Shouldn’t Be Too Comfortable With ACADIA Pharmaceuticals' (NASDAQ:ACAD) Strong Earnings
Even though ACADIA Pharmaceuticals Inc. ( NASDAQ:ACAD ) posted strong earnings recently, the stock hasn't reacted in a...Analyseartikel • Nov 09
ACADIA Pharmaceuticals Inc. Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next
ACADIA Pharmaceuticals Inc. ( NASDAQ:ACAD ) came out with its quarterly results last week, and we wanted to see how the...Narrativ-Update • Sep 26
Global Outreach And Pipeline Programs Will Expand CNS Markets
ACADIA Pharmaceuticals’ consensus price target was revised downward to $29.32 as the Phase 3 failure of ACP-101 in Prader-Willi syndrome modestly reduced pipeline value, though the impact is seen as limited given low expectations and resilience in the core business. Analyst Commentary Bearish analysts cite the Phase 3 failure of ACP-101 in Prader-Willi syndrome (PWS), which missed its primary endpoint, leading to lowered price targets based on reduced near-term pipeline value.Narrativ-Update • Sep 04
Global Outreach And Pipeline Programs Will Expand CNS Markets
Analysts maintained their price target for ACADIA Pharmaceuticals at $29.95 as strong Daybue growth, favorable Nuplazid patent rulings, and strategic R&D focus offset near-term competitive and pipeline uncertainties. Analyst Commentary Bullish analysts are raising price targets citing strong Daybue growth in Q2, but note further acceleration is needed for material upside.Analyseartikel • Aug 09
Results: ACADIA Pharmaceuticals Inc. Beat Earnings Expectations And Analysts Now Have New Forecasts
NasdaqGS:ACAD 1 Year Share Price vs Fair Value Explore ACADIA Pharmaceuticals's Fair Values from the Community and...Analyseartikel • May 30
ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Surges 54% Yet Its Low P/S Is No Reason For Excitement
ACADIA Pharmaceuticals Inc. ( NASDAQ:ACAD ) shares have had a really impressive month, gaining 54% after a shaky period...Analyseartikel • May 09
ACADIA Pharmaceuticals Inc. Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next
ACADIA Pharmaceuticals Inc. ( NASDAQ:ACAD ) just released its first-quarter report and things are looking bullish...Analyseartikel • Mar 03
ACADIA Pharmaceuticals Inc. Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next
ACADIA Pharmaceuticals Inc. ( NASDAQ:ACAD ) last week reported its latest annual results, which makes it a good time...Seeking Alpha • Feb 13
Acadia Pharmaceuticals: Good Progress Means I'm Reversing My 'Sell' Call To 'Buy'
Summary Acadia Pharmaceuticals has shown significant financial improvement, reporting a profit of $82.7m in 2024, compared to a loss of $(107m) in 2023. The company's revenue growth is driven by NUPLAZID and DAYBUE, with 2024 revenue projections of $600m-$610m and $340m-$350m respectively, and overall revenues forecast to exceed $1bn in '25. Acadia's promising pipeline, including ACP-204 and ACP-101, and successful marketing campaigns suggest strong future growth potential. Given the company's profitability, robust pipeline, and undervaluation compared to peers, I am upgrading Acadia from "Sell" to "Buy". Read the full article on Seeking AlphaAnalyseartikel • Jan 08
Why Investors Shouldn't Be Surprised By ACADIA Pharmaceuticals Inc.'s (NASDAQ:ACAD) Low P/S
You may think that with a price-to-sales (or "P/S") ratio of 3.1x ACADIA Pharmaceuticals Inc. ( NASDAQ:ACAD ) is...Seeking Alpha • Nov 27
Acadia: Scope Of Company Goes Beyond Recent SAN711 Licensing Deal For ET
Summary NUPLAZID and DAYBUE are each delivering double-digit percentage net product sales growth. Company is on track to reach more than $1 billion in annualized net product sales in 2025. Next phase of growth could come from two late-stage assets known as ACP-101 for hyperphagia of PWS and ACP-204 for Alzheimer's Disease Psychosis. Company entered into a worldwide license agreement with Saniona to develop and commercialize SAN711 for the treatment of patients with Essential Tremor; Phase 2 study to be initiated in 2026. Read the full article on Seeking AlphaSeeking Alpha • Nov 11
Acadia Pharmaceuticals: Proving The Naysayers Wrong
Summary Today, we are revisiting with mid-cap biopharma Acadia Pharmaceuticals Inc., whose stock surged some 20% last week following Q3 results. The company beat both top and bottom-line expectations and also posted updated FY2024 guidance. Acadia Pharmaceuticals is becoming profitable, has a pristine balance sheet, and is seeing solid growth. An updated analysis around ACAD stock follows in the paragraphs below. Read the full article on Seeking AlphaAnalyseartikel • Nov 08
ACADIA Pharmaceuticals Inc. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Predictions
It's been a pretty great week for ACADIA Pharmaceuticals Inc. ( NASDAQ:ACAD ) shareholders, with its shares surging 18...
Neues Narrativ • Sep 09
Targeted Campaigns And Pipeline Expansions Set To Revolutionize Growth In Neurological Treatment Market
Targeted and DTC campaigns for NUPLAZID aimed at Parkinson's disease psychosis are expected to notably increase patient starts, directly enhancing market share and revenue.Seeking Alpha • Aug 26
Acadia Pharmaceuticals: Nuplazid Performs In Q2 While Daybue Disappoints Again
Summary Shares of Acadia trended lower this year due to Daybue's poor quarterly sales performance, and also due to Nuplazid's failure in the phase 3 trial in schizophrenia patients. The full-year guidance on Daybue was reduced as Acadia is finding fewer new patients, not because of higher patient churn. With most of the headwinds in the rearview mirror, I expect better performance of Daybue going forward. Nuplazid's strong performance remained largely unnoticed given the investor focus on Daybue. Other key pipeline projects are on track with ACP-204, and ACP-101 progressing in phase 2/3 and phase 3 trials, respectively. Read the full article on Seeking AlphaAnalyseartikel • Aug 14
The Strong Earnings Posted By ACADIA Pharmaceuticals (NASDAQ:ACAD) Are A Good Indication Of The Strength Of The Business
Even though ACADIA Pharmaceuticals Inc. ( NASDAQ:ACAD ) posted strong earnings, investors appeared to be underwhelmed...Analyseartikel • Aug 09
ACADIA Pharmaceuticals Inc. Beat Analyst Estimates: See What The Consensus Is Forecasting For This Year
ACADIA Pharmaceuticals Inc. ( NASDAQ:ACAD ) investors will be delighted, with the company turning in some strong...Analyseartikel • Aug 01
ACADIA Pharmaceuticals Inc.'s (NASDAQ:ACAD) Price Is Right But Growth Is Lacking
ACADIA Pharmaceuticals Inc.'s ( NASDAQ:ACAD ) price-to-sales (or "P/S") ratio of 3.9x might make it look like a strong...Analyseartikel • May 23
Shareholders Will Probably Hold Off On Increasing ACADIA Pharmaceuticals Inc.'s (NASDAQ:ACAD) CEO Compensation For The Time Being
Key Insights ACADIA Pharmaceuticals to hold its Annual General Meeting on 29th of May CEO Steve Davis' total...Analyseartikel • Apr 24
ACADIA Pharmaceuticals Inc.'s (NASDAQ:ACAD) Price Is Right But Growth Is Lacking
ACADIA Pharmaceuticals Inc.'s ( NASDAQ:ACAD ) price-to-sales (or "P/S") ratio of 3.8x might make it look like a strong...Gewinn- und Umsatzwachstumsprognosen
| Datum | Umsatz | Gewinne | Freier Cashflow | Bargeld aus operativen Tätigkeiten | Durchschn. Anz. Analysten |
|---|---|---|---|---|---|
| 12/31/2028 | 1,565 | 262 | 188 | 285 | 17 |
| 12/31/2027 | 1,389 | 131 | 207 | 198 | 21 |
| 12/31/2026 | 1,241 | 67 | 206 | 213 | 21 |
| 3/31/2026 | 1,095 | 376 | 212 | 123 | N/A |
| 12/31/2025 | 1,072 | 391 | 105 | 110 | N/A |
| 9/30/2025 | 1,047 | 261 | 99 | 199 | N/A |
| 6/30/2025 | 1,019 | 222 | 88 | 188 | N/A |
| 3/31/2025 | 996 | 229 | 50 | 149 | N/A |
| 12/31/2024 | 958 | 226 | 157 | 158 | N/A |
| 9/30/2024 | 929 | 129 | 203 | 203 | N/A |
| 6/30/2024 | 891 | 31 | 80 | 81 | N/A |
| 3/31/2024 | 814 | -2 | 24 | 64 | N/A |
| 12/31/2023 | 726 | -61 | 17 | 17 | N/A |
| 9/30/2023 | 632 | -149 | -133 | -93 | N/A |
| 6/30/2023 | 551 | -111 | -74 | -34 | N/A |
| 3/31/2023 | 520 | -146 | -56 | -56 | N/A |
| 12/31/2022 | 517 | -216 | -114 | -114 | N/A |
| 9/30/2022 | 512 | -217 | -113 | -113 | N/A |
| 6/30/2022 | 512 | -205 | -130 | -130 | N/A |
| 3/31/2022 | 493 | -214 | -142 | -142 | N/A |
| 12/31/2021 | 484 | -168 | -127 | -126 | N/A |
| 9/30/2021 | 474 | -192 | -133 | -130 | N/A |
| 6/30/2021 | 463 | -262 | -141 | -136 | N/A |
| 3/31/2021 | 458 | -260 | -155 | -147 | N/A |
| 12/31/2020 | 442 | -282 | -144 | -136 | N/A |
| 9/30/2020 | 419 | -268 | -144 | -138 | N/A |
| 6/30/2020 | 393 | -225 | -139 | -134 | N/A |
| 3/31/2020 | 366 | -238 | -137 | -136 | N/A |
| 12/31/2019 | 339 | -235 | N/A | -151 | N/A |
| 9/30/2019 | 300 | -248 | N/A | -161 | N/A |
| 6/30/2019 | 264 | -268 | N/A | -184 | N/A |
| 3/31/2019 | 238 | -276 | N/A | -186 | N/A |
| 12/31/2018 | 224 | -245 | N/A | -167 | N/A |
| 9/30/2018 | 208 | -249 | N/A | -158 | N/A |
| 6/30/2018 | 185 | -252 | N/A | -174 | N/A |
| 3/31/2018 | 158 | -256 | N/A | -192 | N/A |
| 12/31/2017 | 125 | -289 | N/A | -218 | N/A |
| 9/30/2017 | 93 | -299 | N/A | -251 | N/A |
| 6/30/2017 | 63 | -306 | N/A | -242 | N/A |
| 3/31/2017 | 33 | -309 | N/A | -240 | N/A |
| 12/31/2016 | 17 | -271 | N/A | -208 | N/A |
| 9/30/2016 | 5 | -238 | N/A | -182 | N/A |
| 6/30/2016 | 0 | -206 | N/A | -165 | N/A |
| 3/31/2016 | 0 | -174 | N/A | -138 | N/A |
| 12/31/2015 | 0 | -164 | N/A | -122 | N/A |
| 9/30/2015 | 0 | -147 | N/A | -105 | N/A |
| 6/30/2015 | 0 | -133 | N/A | -91 | N/A |
Analystenprognosen zum zukünftigen Wachstum
Einkommen vs. Sparrate: ACADDas prognostizierte Gewinnwachstum (12.1% pro Jahr) liegt über der Sparquote (3.5%).
Ertrag vs. Markt: ACADDie Erträge des Unternehmens (12.1% pro Jahr) werden voraussichtlich langsamer wachsen als der Markt US (16.8% pro Jahr).
Hohe Wachstumserträge: ACADDie Erträge des Unternehmens werden voraussichtlich steigen, jedoch nicht deutlich.
Einnahmen vs. Markt: ACADDie Einnahmen des Unternehmens (10.1% pro Jahr) werden voraussichtlich langsamer wachsen als der Markt US (11.6% pro Jahr).
Hohe Wachstumseinnahmen: ACADDie Einnahmen des Unternehmens (10.1% pro Jahr) werden voraussichtlich langsamer wachsen als 20% pro Jahr.
Wachstumsprognosen für den Gewinn je Aktie
Künftige Eigenkapitalrendite
Künftige Eigenkapitalrendite: ACADDie Eigenkapitalrendite des Unternehmens wird in 3 Jahren voraussichtlich niedrig sein (17.1%).
Wachstumsunternehmen entdecken
Unternehmensanalyse und Finanzdaten Status
| Daten | Zuletzt aktualisiert (UTC-Zeit) |
|---|---|
| Unternehmensanalyse | 2026/05/20 05:09 |
| Aktienkurs zum Tagesende | 2026/05/20 00:00 |
| Gewinne | 2026/03/31 |
| Jährliche Einnahmen | 2025/12/31 |
Datenquellen
Die in unserer Unternehmensanalyse verwendeten Daten stammen von S&P Global Market Intelligence LLC. Die folgenden Daten werden in unserem Analysemodell verwendet, um diesen Bericht zu erstellen. Die Daten sind normalisiert, was zu einer Verzögerung bei der Verfügbarkeit der Quelle führen kann.
| Paket | Daten | Zeitrahmen | Beispiel US-Quelle * |
|---|---|---|---|
| Finanzdaten des Unternehmens | 10 Jahre |
| |
| Konsensschätzungen der Analysten | +3 Jahre |
|
|
| Marktpreise | 30 Jahre |
| |
| Eigentümerschaft | 10 Jahre |
| |
| Verwaltung | 10 Jahre |
| |
| Wichtige Entwicklungen | 10 Jahre |
|
* Beispiel für US-Wertpapiere, für nicht-US-amerikanische Wertpapiere werden gleichwertige regulatorische Formulare und Quellen verwendet.
Sofern nicht anders angegeben, beziehen sich alle Finanzdaten auf einen Jahreszeitraum, werden aber vierteljährlich aktualisiert. Dies wird als Trailing Twelve Month (TTM) oder Last Twelve Month (LTM) Daten bezeichnet. Erfahren Sie mehr.
Analysemodell und Schneeflocke
Einzelheiten zu dem Analysemodell, mit dem dieser Bericht erstellt wurde, finden Sie auf unserer Github-Seite. Außerdem bieten wir Leitfäden zur Verwendung unserer Berichte und Tutorials auf YouTube an.
Erfahren Sie mehr über das Weltklasse-Team, das das Simply Wall St-Analysemodell entworfen und entwickelt hat.
Metriken für Industrie und Sektor
Unsere Branchen- und Sektionskennzahlen werden alle 6 Stunden von Simply Wall St berechnet. Details zu unserem Verfahren finden Sie auf Github.
Analysten-Quellen
ACADIA Pharmaceuticals Inc. wird von 37 Analysten beobachtet. 21 dieser Analysten hat die Umsatz- oder Gewinnschätzungen übermittelt, die als Grundlage für unseren Bericht dienen. Die von den Analysten übermittelten Daten werden im Laufe des Tages aktualisiert.
| Analyst | Einrichtung |
|---|---|
| Joel Beatty | Baird |
| null null | Baird |
| Jack Allen | Baird |